Answers are grounded in this paper and cite their sources.
Over the last few years, new molecular biological techniques have improved sensitivity and specificity of detection of primary and recurrent cancer in different types of neoplasia. In the field of endocrinology, thyroid cancer makes up more than 90% of all endocrine cancers and accounts for 63% of deaths from endocrine cancer (Correa & Chen, 1995; Hundahl et al., 1998), with an increasing incidence of the disease worldwide (Franceschi et al., 1993; Pettersson et al., 1996; Parker et al., 1997). Despite advances in the treatment of thyroid cancer, disease recurrence and metastasis may occur in as many as 20% of patients (Loh et al., 1997). In this context, molecular detection of tissue or tumour-specific DNA or mRNA in peripheral blood and surgical/fine-needle aspiration biopsy (FNAB) by PCR-based techniques have been proposed as new diagnostic tools (Johnson et al., 1995; Haber, 1998). Nevertheless, there is much debate regarding the clinical utility of PCR-based techniques in diagnosis and follow-up patients with thyroid cancer. Therefore, it seems an appropriate time to make a critical evaluation of the standing of molecular assays for thyroid cancer. Molecular techniques for the diagnosis of cancer in thyroid nodules are most needed for patients in whom conventional FNAB cytology yields an indeterminate diagnosis of ‘follicular neoplasm’, which are patients who have either adenomas or low-grade carcinomas. In a recent study, cytological findings of follicular neoplasm on FNAB were confirmed by the histological diagnosis of follicular carcinoma in only 5%, while 81% had follicular adenomas on histological evaluation (Amrikachi et al., 2001). In contrast, cytological diagnosis of papillary carcinoma was confirmed by the histological diagnosis in 93%. Additionally, cytological examination may not provide a conclusive diagnosis when biopsy samples are found to be ‘unsatisfactory’, ‘intermediate’ or ‘suspicious’. A molecular-based diagnostic approach may provide a more objective method to assure reliable diagnosis in these cases. Postoperative surveillance of patients with thyroid cancer has several limitations. Since the 1970s, serum thyroglobulin has been the established tumour marker of residual and recurrent differentiated thyroid carcinoma (Herle & Uller, 1975; Duren et al., 1999; Spencer et al., 1999). In recent years, recombinant human TSH (rhTSH) has been administered to avoid the necessity for thyroxine withdrawal hypothyroidism, previously necessary to achieve adequate TSH stimulation (Haugen et al., 1999). However, the use of rhTSH is expensive and may potentially stimulate cancer growth. Furthermore, antithyroglobulin antibodies can be detected in up to 20% of patients with thyroid cancer and may interfere with the serum thyroglobulin immunoassay (Spencer et al., 1998), although the presence of antithyroglobulin antibodies may perhaps be a sign of residual thyroid tissue itself, leading to appropriate diagnostic and therapeutic consequences. Therefore, a molecular-based, sensitive and convenient screening test to diagnose recurrent thyroid cancer, not requiring TSH stimulation or the absence of thyroglobulin antibodies, would be useful. Molecular diagnostic evaluation of FNAB or surgical samples requires certainty of the tissue or cell of origin. Therefore, a prerequisite for the use of polymerase chain reaction (PCR)-based methods is the existence of tissue or tumour-specific DNA or RNA. Recently, new genetic alterations have been reported in thyroid cancer, e.g. two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutations or PAX8-PPARγ rearrangement in follicular thyroid carcinomas (Kroll et al., 2000; Nikiforova et al., 2003) and methylation of TSH-receptor for epithelial thyroid cancers (Xing et al., 2003). However, these results have to be confirmed and evaluated further. Together, to date a thyroid cancer-specific molecular marker has not been clearly identified. Thus, more general transcripts, which were supposed to be tumour-specific, have been analysed. Out of the numerous molecular markers described for FNAB, some promising candidates will be discussed in detail, while others will be mentioned in passing. Galectin-3 (GAL-3) is a β-galactosil-binding protein involved in regulating cell–cell and cell–matrix interactions. In addition, galectins have been implicated in the initiation and regulation of cell growth and malignant transformation (Xu et al., 1995; Fernandez et al., 1997). GAL-3 has been widely used as a marker of thyroid cancer in immunohistochemistry. Normal thyroid tissue and benign nodules have been considered not to express GAL-3, while its expression has been demonstrated in malignant transformation of follicular cells (Saggiorato et al., 2001). Used as an additional marker, most studies evaluating GAL-3 as a marker in immunohistochemistry reported high sensitivity and specificity in differentiating malignant from benign thyroid disease for both FNAB-derived cytology and conventional histology (Orlandi et al., 1998; Inohara et al., 1999; Bartolazzi et al., 2001; Lloyd, 2001; Saggiorato et al., 2001). However, there is some concern about the specificity of GAL-3 expression, because GAL-3 expression has been found in Hashimoto's thyroiditis (HT) using immunohistochemistry (Bartolazzi et al., 2001; Niedziela et al., 2002), and an ubiquitous expression of GAL-3 mRNA in benign and malignant thyroid tumours using RT–PCR has even been described (Takano et al., 2003). Nevertheless, if the diagnosis of HT is excluded, the value of GAL-3 in the diagnosis of malignancy still appears to be high (Niedziela et al., 2002). Taken together, recent data indicate that a search for GAL-3 protein overexpression by immunohistochemical methods, but not by RT–PCR, may yield an additional marker of malignant potential of thyroid nodular lesions (Bartolazzi et al., 2003; Giannini et al., 2003). Further studies are needed to evaluate whether GAL-3 might be a useful marker in addition to the currently available diagnostic tools for the preoperative diagnosis of malignant thyroid tumours (Table 1). CD44 is a polymorphic family of immunologically related integral membrane glycoproteins associated with cell matrix adhesion, lymphocyte activation and targeting, and tumour growth and metastasis. CD44 can be expressed on the cell surface as a standard receptor (CD44s), the receptor mainly for hyaluronic acid, as well as multiple isoforms (CD44v; Naor et al., 1997). Some variant isoforms, especially those containing sequences encoded by v6–v10, are overexpressed in several human neoplasms, including thyroid cancer, particularly in the papillary variant (Figge et al., 1994; Ermak et al., 1996). First reports of successful differentiation of thyroid papillary carcinoma from other lesions by CD44 immunostaining of thyroid fine-needle aspirates (Chhieng et al., 1997) were followed by studies using RT–PCR to detect CD44 mRNA in leftover cells inside the needle used for FNAB (Takano et al., 1997b; Aogi et al., 1999; Gasbarri et al., 1999). These studies suggested that thyroid tumours may be more accurately diagnosed by a combination of cytological examination and detection of CD44 variants in RNA obtained by FNAB, in particular when co-expression of CD44v6 and GAL-3 was detectable. However, CD44 exons were also present in transcripts in a high proportion of benign samples (Aogi, 1999). Taken together, in thyroid cancer the clinical applicability of CD44v detected by RT–PCR has still to be determined, in particular in the light of the excellent specificity and sensitivity of FNAB conventional cytology in papillary thyroid carcinoma. Oncofetal fibronectin has been proposed as a possible tool for the preoperative diagnosis of thyroid carcinomas, based on the finding that the expression of oncofetal fibronectin mRNA was significantly increased in papillary and anaplastic carcinomas, compared to normal thyroid tissues and follicular adenomas. Several reports using oncofetal fibronectin as a marker of malignancy showed that combined examination using both RT–PCR and cytological approaches may contribute to a more precise preoperative diagnosis of papillary and anaplastic carcinomas (Takano et al., 1997a, 1998a, 1998b, 1999a, 2000; Higashiyama et al., 1999). However, other groups found that oncofetal fibronectin overexpression may not yield an additional marker of papillary and anaplastic carcinomas when detected by RT–PCR, because oncofetal fibronectin mRNA expression was found in 40% of adenomas as well (Giannini et al., 2003). Together, the molecular detection of this particular marker will not benefit patients with the typical diagnostic problem, i.e. ‘follicular neoplasm’ on cytology, and most papillary lesions can be diagnosed by conventional cytology. However, additional studies are necessary to determine whether detection of oncofetal fibronectin mRNA expression might be helpful in diagnosing patients with papillary lesions and limited cellularity for conventional cytology. Telomerase, the ribonucleoprotein enzyme that elongates chromosomal ends or telomeres, is repressed in most normal somatic cells, but reactivated in transformed cells to compensate for the progressive erosion of the telomeres during cell divisions. Reactivation of telomerase and its catalytic component, the human telomerase reverse transcriptase (hTERT), has been widely reported in endocrine neoplasms and in hormone-related cancers, amongst others in thyroid cancer (Orlando & Gelmini, 2001). Using RT–PCR, detection of hTERT mRNA was reported to be the most specific for the detection of thyroid carcinoma in frozen tissue samples as a single analyte, but diagnostic accuracy was increased by the combination of telomerase and CD44 analyses (Aogi et al., 1999). This finding was supported by other studies reporting that the detection of hTERT expression in thyroid FNAB may be accurate in distinguishing benign from malignant thyroid lesions (Saji et al., 1999; Zeiger et al., 1999), although a recent study clearly indicated that the extent of the differences in hTERT mRNA expression between benign and malignant thyroid tumours require further investigation (Liou et al., 2003). In addition, two other studies using the telomeric repeat amplification protocol assay followed by enzyme-linked immunosorbent assay found that telomerase assays did not add any additional information to FNAB alone, and presence of lymphocytes can give false positive results (Sebesta et al., 2001; Trulsson et al., 2003). Together, this marker is unlikely to make the differentiation between benign and malignant thyroid tumours easier. The high mobility group I (HMGI) proteins represent a class of nuclear proteins involved in the regulation of chromatin structure and function. HMGI(Y), one of the members of this class, is expressed at high levels during embryogenesis and in malignant tumours such as thyroid carcinoma (Dal Cin et al., 1999) but at generally low levels in normal adult human tissues. In one study, HMGI(Y) expression was analysed by a combination of immunohistochemistry and RT–PCR in 358 thyroid tissue samples that were representative of the spectrum of thyroid tumour pathology (Chiappetta et al., 1998). The findings of this study indicated the HMGI(Y) protein as a potential marker for thyroid carcinoma (Chiappetta et al., 1998), but further evaluation of this is warranted. The RET proto-oncogene is located on chromosome 10q11–2. RET activation has been found in papillary thyroid cancer (PTC) tumours and is therefore called RET/PTC. Activated forms of the RET proto-oncogene are the consequence of oncogenic rearrangements fusing the tyrosine kinase domain of the RET gene with the 5′ domain of different genes. Therefore, several variants of RET/PTC have been observed, the three main types designated as RET/PTC1, -2 and -3 (Grieco et al., 1990). Two other types of RET rearrangements (RET/PTC4 and -5) have also been described recently. In most populations, generation of the fusion transcripts is identified in almost half of PTC lesions. One study examined thyroid aspirates for the presence of RET/PTC gene rearrangements by RT–PCR for the three most common RET/PTC gene rearrangements (RET/PTC-1, -2 and -3). In this study, no false positive results were obtained. In addition, the identification of RET/PTC gene rearrangements refined the diagnosis that would otherwise have been considered indeterminate or insufficient for cytological diagnosis in several cases (Cheung et al., 2001). Another study reported RET/PTC activation, in particular the RET/PTC1 isoform, in a significant number of cases of Hurthle cell adenomas and carcinomas, but not in hyperplastic nodules and controls (Chiappetta et al., 2002). Although these results would indicate that RET/PTC is a genetic event common to papillary carcinomas and a specific marker that can be applied to fine-needle aspiration biopsies and improves the diagnosis of malignancy, RET/PTC rearrangements have been found in benign nodules as well (Elisei et al., 2001). In addition, on the basis of a growing number of RET/PTC oncoproteins, evaluation of only one, two or three isoforms appears to be incomplete in most cases. In medullary thyroid carcinoma (MTC), laboratory tests for preoperative diagnosis and postoperative follow-up are performed using basal as well as pentagastrin-stimulated serum calcitonin (CT), which is supplemented by estimation of serum levels of carcinoembryonic antigen (CEA; Marsh et al., 1995; Heshmati et al., 1997; Giuffrida & Gharib, 1998). In contrast to papillary and follicular thyroid carcinoma, to date only few studies have been published concerning the preoperative diagnosis of MTC using PCR-based methods (Bugalho et al., 2000; Russo et al., 1997; Takano et al., 1999a). The reason for that discrepancy may be that patients with MTC are usually readily diagnosed by conventional cytology and serum calcitonin measurements. These studies reported a somatic RET proto-oncogene mutation in FNAB obtained from a patient tested negative for RET proto-oncogene germinal mutation (Russo et al., 1997), and calcitonin, CEA and RET proto-oncogene mRNA in leftover cells of FNAB in all preoperative samples from MTCs, but not in other tumours or normal thyroid tissues (Takano et al., 1999a; Bugalho et al., 2000), respectively. However, all MTC patients in these studies presented with ‘high levels’ of serum calcitonin, whereas all of the non-MTC patients, except one, had serum calcitonin levels below the threshold. Therefore, RT–PCR-based assays did not add any additional information to measurement of serum calcitonin alone. The application of RT–PCR to detect circulating thyroid-specific mRNA in recurrent thyroid cancer was first reported in a 1996 study, in which all patients with thyroid carcinoma and metastases were tested positive for circulating thyroglobulin (TG) mRNA, while patients without metastases were tested negative (Ditkoff et al., 1996). In a subsequent study (Tallini et al., 1998), circulating mRNA transcripts of TG, thyroid peroxidase (TPO) and RET/PTC1 were used as tumour markers in patients with thyroid disease. Although there was a correlation between existence of these transcripts in peripheral blood and diagnosis of thyroid carcinoma, TG and TPO mRNA transcripts could be detected in peripheral blood of all control subjects as well as in several human cell lines when PCR assay sensitivity was increased. Finally, an optimistic study was published (Ringel et al., 1998), which reported a RT–PCR assay to detect blood borne TG mRNA that was more sensitive than the conventional TG serum assay. However, the assay was also positive in all control subjects. But using magnetic cell sorting, the authors were able to identify putative thyroid cells circulating in peripheral blood as a source of the positive PCR results in controls. With newly developed quantitative RT–PCR assays, additional studies of these authors demonstrated that the median TG mRNA value for patients with no uptake in 131I whole-body scans was significantly lower than the median values for patients with thyroid bed uptake or with detectable thyroid tissue at any site. Similar differences between these groups were seen after T4 withdrawal and for the patients with circulating anti-TG antibodies, when analysed separately (Ringel et al., 1999; Wingo et al., 1999; Fenton et al., 2001). Additionally, results of some other studies implicated a clinically useful application of TG-mRNA assays in patients with thyroid cancer (Biscolla et al., 2000; Bellantone et al., 2001; Savagner et al., 2002). However, in an earlier study by the authors (Bojunga et al., 2000), only a weak correlation between the detection of circulating TG-mRNA and the diagnosis of thyroid cancer was found with low assay sensitivities, whereas at high RT–CR sensitivity, TG-mRNA expression was found not to be specific for thyroid tissue and was not correlated with a diagnosis of thyroid cancer in patients. The conclusion was that TG-mRNA is not a tissue-specific marker, which could be confirmed by testing different human tissues for TG- mRNA expression. Our finding of lack of tissue-specificity of TG-mRNA has been reproduced by many other groups (see below) and now, there is evidence that detection of TG-mRNA in peripheral blood might reflect detection of illegitimate transcription in cell types of nonthyroid origin – e.g. lymphocytes – as it has been described earlier (Chelly et al., 1989; Kimoto, 1996). Thus, circulating TG-mRNA is not a reliable tumour marker for the follow-up of patients with thyroid cancer (Bugalho et al., 2001; Takano et al., 2001; Eszlinger et al., 2002; Denizot et al., 2003; Span et al., 2003; Elisei et al., 2004). Studies are summarized in Table 2. Searching for local relapse or distant metastases in medullary thyroid carcinoma is often very difficult and includes laboratory tests as mentioned above as well as selective venous catheterization, ultrasound, octreotide scan, computerized tomography and magnetic resonance imaging (Marsh et al., 1995). Therefore, molecular detection of circulating tumour cells may again represent a new approach in order to improve early diagnosis of metastasized MTC. One study has been published that has explored blood-borne cytokeratin 20 mRNA as a potential tumour marker in thyroid cancer, especially MTC (Weber et al., 2000). However, the limitation of this study was that tissue specificity of the transcripts was not evaluated and as others have shown (Jung et al., 1999), the detection of micrometastasis by cytokeratin 20 RT–PCR is limited due to stable background transcription in granulocytes. Another study (Saller et al., 2002) investigated circulating calcitonin (CT) mRNA as tumour marker in MTC, and the authors concluded that the results of the RT–PCR-based procedure seem to reflect tumour spread and aggressiveness. However, these results have not been confirmed yet. In the study of the authors (Bojunga et al., 2001), no correlation between the presence of circulating CT/CEA mRNA and clinical staging of patients with MTC was found. Initial studies using RT–PCR based methods in the preoperative diagnosis of thyroid cancer reported encouraging results, although sensitivity and positive predictive value of these methods were even worse in most cases compared to ‘conventional’ methods (summarized in Table 1). Additionally, in medullary carcinoma, the existing serum protein markers are quite sensitive for establishing the diagnosis. Compared to established methods, to date it has not been proven that RT–PCR-based methods are significantly more sensitive and specific, facts that would rationalize their considerably higher costs and expenditure of energy and time. However, new immunohistochemical markers may improve diagnostic accuracy. In particular, GAL-3 seems to be a reliable presurgical marker to differentiate between follicular adenomas and follicular carcinomas as well (Bartolazzi et al., 2001; Saggiorato et al., 2001). In the postoperative follow-up of patients with thyroid cancer, optimism has given way to disillusionment regarding the use of TG-mRNA assays in clinical practice 8 years after the initial report. Over the years, several technical limitations of the RT–PCR-based approach has been demonstrated, including missing thyroid-specificity of TG-mRNA transcripts, high sensitivity at the expense of poor specificity, sample contaminations and TG splice variants, and variability in results due to sample handling. In addition, quantitative approaches were not able to define reliable cut-off levels for circulating TG-mRNA. Furthermore, biological limitations of molecular assays seemed to be neglected in the past, e.g. the experimental evidence of an intermittent release of tumour cells in the bloodstream (Ghossein & Rosai, 1996; Seiter et al., 2001), a fact making assays detecting circulating cells less reliable. In addition, the presence of circulating tumour cells does not necessarily mean metastatic disease, a phenomenon that has been termed ‘metastatic inefficiency’ (for review see Weiss et al., 1990). The vast of tumour cells that the bloodstream not to metastases but are by and et al., 1998; et al., 2000). Together, PCR-based techniques may improve the preoperative diagnosis and staging of patients with thyroid and therefore to avoid However, there is a growing number of studies on the use of immunostaining especially the studies published not give for the use of more and less specific RT–PCR In addition, there is evidence that TG-mRNA assays using peripheral blood samples are not clinically than the TG in the postoperative surveillance of patients with thyroid cancer. Thus, the use of these assays be for the follow-up of patients with thyroid cancer.
No takes yet. Share an insight, caveat, or question.
Bojunga et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: